文献速递认知障碍与痴呆

大流行前阿尔茨海默病生物标志物与认知正常成人COVID-19封控期间焦虑抑郁症状的关系

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
PubMed 文献 · Neurology · 2022-08-02

这项回顾性观察研究纳入921名认知正常老年人(254名有AD生物标志物),发现β-淀粉样蛋白阳性、照护者身份、女性、较年轻和较低教育程度与封控期间更重的焦虑抑郁症状相关;校正封控前焦虑抑郁水平后,较低脑脊液IL-6水平也与更高HADS评分相关,结果主要由女性驱动。

要点

  • β-淀粉样蛋白阳性与封控期间焦虑抑郁症状加重相关(B=3.73,95%CI 1.1-6.36,p=0.006)。
  • 女性、照护者、较年轻和较低教育程度与封控期间更高HADS评分相关。
  • 校正封控前焦虑抑郁水平后,较低脑脊液IL-6与更高HADS评分相关(B=-5.11,95%CI -10.1至-0.13,p=0.044)。

核心结论

  • AD相关病理生理和神经炎症与COVID-19封控期间更重的焦虑抑郁症状相关,尤其在女性中。

研究设计与样本

  • 回顾性观察研究,纳入阿尔茨海默病与家族队列中认知正常老年人921名(254名有AD生物标志物),多数有散发性AD家族史。

主要发现

  • β-淀粉样蛋白阳性(B=3.73;95%CI 1.1至6.36;p=0.006)、照护者身份(B=1.37;95%CI 0.24至2.5;p=0.018)、女性(B=1.95;95%CI 1.1至2.79;p<0.001)、较年轻年龄(B=-0.12;95%CI -0.18至-0.052;p<0.001)和较低教育程度(B=-0.16;95%CI -0.28至-0.042;p=0.008)与封控期间更重焦虑抑郁症状相关。
  • 校正封控前焦虑抑郁水平后,较低脑脊液IL-6水平与更高HADS评分相关(B=-5.11;95%CI -10.1至-0.13;p=0.044)。
  • 结果独立于压力相关变量和生活方式改变, stratified分析显示关联主要由女性驱动。

临床怎么用

  • 作者认为,AD病理生理可能增加对应激源的精神症状反应,这一关联可能提示疫情后AD风险人群临床预后更差,值得临床医生考虑。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Increased anxious-depressive symptomatology is observed in the preclinical stage of Alzheimer disease (AD), which may accelerate disease progression. We investigated whether β-amyloid, cortical thickness in medial temporal lobe structures, neuroinflammation, and sociodemographic factors were associated with greater anxious-depressive symptoms during the COVID-19 confinement. METHODS: This retrospective observational study included cognitively unimpaired older adults from the Alzheimer's and Families cohort, the majority with a family history of sporadic AD. Participants performed the Hospital Anxiety and Depression Scale (HADS) during the COVID-19 confinement. A subset had available retrospective (on average: 2.4 years before) HADS assessment, amyloid [18F] flutemetamol PET and structural MRI scans, and CSF markers of neuroinflammation (interleukin-6 [IL-6], triggering receptor expressed on myeloid cells 2, and glial fibrillary acidic protein levels). We performed multivariable linear regression models to investigate the associations of prepandemic AD-related biomarkers and sociodemographic factors with HADS scores during the confinement. We further performed an analysis of covariance to adjust by participants' prepandemic anxiety-depression levels. Finally, we explored the role of stress and lifestyle changes (sleep patterns, eating, drinking, smoking habits, and medication use) on the tested associations and performed sex-stratified analyses. RESULTS: We included 921 (254 with AD biomarkers) participants. β-amyloid positivity (B = 3.73; 95% CI = 1.1 to 6.36; p = 0.006), caregiving (B = 1.37; 95% CI 0.24-2.5; p = 0.018), sex (women: B = 1.95; 95% CI 1.1-2.79; p < 0.001), younger age (B = -0.12; 95% CI -0.18 to -0.052; p < 0.001), and lower education (B = -0.16; 95% CI -0.28 to -0.042; p = 0.008) were associated with greater anxious-depressive symptoms during the confinement. Considering prepandemic anxiety-depression levels, we further observed an association between lower levels of CSF IL-6 (B = -5.11; 95% CI -10.1 to -0.13; p = 0.044) and greater HADS scores. The results were independent of stress-related variables and lifestyle changes. Stratified analysis revealed that the associations were mainly driven by women. DISCUSSION: Our results link AD-related pathophysiology and neuroinflammation with greater anxious-depressive symptomatology during the COVID-19-related confinement, notably in women. AD pathophysiology may increase neuropsychiatric symptomatology in response to stressors. This association may imply a worse clinical prognosis in people at risk for AD after the pandemic and thus deserves to be considered by clinicians. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier NCT02485730.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Akinci M, Peña-Gómez C, Operto G, et al. Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults. Neurology. 2022. PMID: 35918160. doi:10.1212/WNL.0000000000200948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。